Gibtulio 25 Mg Tablet (Empagliflozin)

Description

Introduction

Gibtulio 25 Mg Tablet is presented as a tablet containing 25 mg of empagliflozin for type 2 diabetes. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a class of medicines used to lower blood glucose. This description explains the active ingredient’s established action and relevant precautions. A healthcare professional can provide guidance about the supplied product and its place in a treatment plan.

What Is It?

The stated strength is 25 mg of empagliflozin per tablet. Strength describes the amount of active ingredient in the tablet; it does not specify an appropriate dose for an individual. The product page identifies the dosage form as a tablet. Gibtulio’s inactive ingredients, coating and Australian approval status have not been verified. Anyone who needs those details, including for an allergy or intolerance, should ask a pharmacist to check the supplied pack.

How Does It Work?

The kidneys filter glucose from the blood and normally return much of it to the bloodstream. Empagliflozin blocks SGLT2, a protein involved in returning glucose. More glucose then leaves the body in urine, helping to lower blood glucose. This action does not depend on increasing insulin release. Its glucose-lowering effect does depend on kidney function and may be reduced when kidney function is impaired. Passing more glucose in urine can also increase urine volume.

Common Uses

Empagliflozin is used with diet and physical activity to improve blood glucose control in type 2 diabetes. It may be used alone or with other glucose-lowering medicines when clinically appropriate. The Gibtulio product page identifies type 2 diabetes as its indication. Other uses authorised for particular empagliflozin brands should not be assumed to apply to Gibtulio. A healthcare professional can advise whether this product fits a specific treatment plan.

Available Strengths

This family is available in 10 mg, 25 mg.

Key Features

• Stated active ingredient: empagliflozin.
• Stated strength: 25 mg per tablet.
• Dosage form: tablet for oral use.
• Medicine class: SGLT2 inhibitor.
• Glucose-lowering action: increased excretion of glucose in urine.

Details such as the tablet’s appearance, coating and inactive ingredients should be checked against the supplied product information rather than assumed from another empagliflozin tablet.

Benefits

• Empagliflozin can improve blood glucose control in people with type 2 diabetes.
• It works through the kidneys by reducing glucose reabsorption.
• Its different mechanism allows it to be considered alongside other glucose-lowering treatments when appropriate.

The amount of glucose lowering varies. Kidney function, other medicines and the wider treatment plan all matter when assessing the expected effect. These established characteristics do not mean that Gibtulio is appropriate for every person or that it has benefits beyond those verified for this product.

Possible Side Effects

• Genital fungal infections, including thrush, may occur.
• Urinary tract infections and more frequent urination may occur.
• Fluid loss may lead to thirst, dizziness or low blood pressure.
• Low blood glucose is more likely when empagliflozin is used with insulin or a sulfonylurea.
• Serious reported problems include ketoacidosis, severe urinary tract infection and a rare, severe infection of the genital or perineal area.

Possible symptoms of ketoacidosis include nausea, vomiting, abdominal pain, unusual tiredness and shortness of breath. It may occur even without a very high blood glucose reading. Severe pain, redness or swelling around the genitals or perineum, particularly with fever or feeling unwell, also needs urgent medical assessment.

Precautions

• Kidney function affects the glucose-lowering action and can influence treatment decisions.
• Dehydration or low blood pressure may increase the risk of problems related to fluid loss.
• A history of recurrent genital or urinary tract infections is relevant to a clinical review.
• Empagliflozin is not a treatment for type 1 diabetes.
• A previous episode of ketoacidosis or an allergy to empagliflozin should be raised with a healthcare professional.

A pharmacist can check the supplied tablet’s complete ingredient information if an inactive-ingredient allergy or intolerance is a concern.

Additional Precautions

• Acute illness, dehydration, reduced food intake and surgery can increase the risk of ketoacidosis. A healthcare professional should advise on treatment during these circumstances.
• Pregnancy or breastfeeding should be discussed with a healthcare professional before use.
• Older people may be more vulnerable to fluid loss and low blood pressure.
• Urine may test positive for glucose because of empagliflozin’s action. Clinicians interpreting test results should know about its use.
• Routine foot care remains an important part of diabetes care.

Storage Instructions

• Follow the storage directions printed on the supplied Gibtulio pack. A product-specific temperature limit has not been verified.
• Keep tablets in their supplied packaging and out of the sight and reach of children.
• Check the expiry date on the packaging before use.
• Ask a pharmacist for guidance if the pack is damaged or its storage directions are unclear.
• Ask a pharmacy how to dispose of unused or expired tablets.

How to Take

• Follow the prescription and directions on the supplied label.
• The 25 mg tablet strength alone does not determine an individual dose or schedule.
• Ask a pharmacist to confirm any instructions specific to Gibtulio about food, swallowing or splitting the tablet.
• Seek professional guidance about a missed dose, vomiting or difficulty taking medicine during illness.

Changes to a prescribed regimen require advice based on the individual’s circumstances and the supplied product.

Drug Interactions

• Insulin and sulfonylureas can increase the risk of low blood glucose when used with empagliflozin.
• Loop and thiazide diuretics may add to fluid loss and increase the risk of dehydration or low blood pressure.
• Empagliflozin may lower blood lithium concentrations. A clinician may arrange closer lithium monitoring when treatment changes.
• A healthcare professional should review prescription medicines, non-prescription medicines and supplements used alongside it.

The relevance of an interaction depends on the full medicine list and clinical circumstances.

Why Choose This Product?

• It is presented as an oral tablet containing empagliflozin at a stated strength of 25 mg.
• Empagliflozin has an established glucose-lowering action relevant to type 2 diabetes.
• The active ingredient can be considered with other diabetes treatments when a clinician judges the combination appropriate.

Selection of an empagliflozin product depends on the prescription, supplied product information and individual clinical factors. Ask a healthcare professional for product-specific guidance.

Frequently Asked Questions (FAQs)

What is the stated active ingredient?

Gibtulio 25 Mg Tablet is identified as containing empagliflozin.

What does the 25 mg strength mean?

It is the stated amount of empagliflozin in one tablet, not a dose recommendation for everyone.

What type of medicine is empagliflozin?

It is an SGLT2 inhibitor that increases glucose excretion in urine.

What is this product presented for?

The product page identifies type 2 diabetes. A healthcare professional can confirm whether it fits an individual treatment plan.

Can empagliflozin be used with other diabetes medicines?

It may be used in combination when clinically appropriate. Some combinations increase the risk of low blood glucose.

Why might urination increase?

Its action increases glucose in urine and can also increase urine volume.

Does kidney function affect its action?

Yes. Reduced kidney function can lessen its blood glucose effect.

What symptoms need urgent attention?

Persistent vomiting, abdominal pain, unusual tiredness, shortness of breath or severe genital or perineal pain and swelling need urgent medical assessment.

Are the inactive ingredients known?

They have not been verified for Gibtulio. Ask a pharmacist to check the supplied packaging if an ingredient is a concern.

Related Products

• Gibtulio 10 Mg Tablet (Empagliflozin)
• Gibtulio 25 Mg Tablet (Empagliflozin)
• Voglibose 0.3 mg Australia
• Glimepiride 4 mg Australia
• Repaglinide 1 mg Australia
• Acarbose 50 mg Australia